MDT-AP-0049
Med · Medulloblastoma
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- Med
- cancer_type_detailed
- —
- subtype
- Medulloblastoma
- cancer_type
- Med
- subtype
- Medulloblastoma
- overall_survival_months
- 121.44
- os_event
- false
- age_years
- 11
- sex
- M
- new_clusters
- C4
- umap1_2d
- 2.654949999
- umap2_2d
- 4.890381802
- umap1_3d
- 0.389394965
- umap2_3d
- -0.494602913
- umap3_3d
- -0.680178064
- dataset
- Med-Taylor
GSVA pathway preview (0 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
10 twins match this tumor's tissue · 0 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | MDT-AP-0809 | Med | Medulloblastoma | 0.809 |
| 2 | MDT-AP-0386 | Med | Medulloblastoma | 0.785 |
| 3 | MDT-AP-0565 | Med | Medulloblastoma | 0.767 |
| 4 | s0122319 | — | — | 0.750 |
| 5 | BS_SKGJ5SY9 | Med | Medulloblastoma | 0.742 |
| 6 | MDT-AP-2576 | Med | Medulloblastoma | 0.730 |
| 7 | MDT-AP-2874 | Med | Medulloblastoma | 0.710 |
| 8 | MDT-AP-0723 | Med | Medulloblastoma | 0.707 |
| 9 | MDT-AP-0732 | Med | Medulloblastoma | 0.706 |
| 10 | MNG1120 | — | — | 0.701 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 29 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| E2F_TARGETS | 0.490 | Inavolisib | — uncovered |
| ANGIOGENESIS | 0.450 | Remibrutinib | — uncovered |
| PANCREAS_BETA_CELLS | 0.420 | Cobimetinib | — uncovered |
| EPITHELIAL_MESENCHYMAL_TRANSITION | 0.400 | Inavolisib | — uncovered |
| G2M_CHECKPOINT | 0.390 | Inavolisib | — uncovered |
| ALLOGRAFT_REJECTION | 0.360 | Idelalisib | — uncovered |
| KRAS_SIGNALING_UP | 0.350 | Inavolisib | — uncovered |
| INTERFERON_GAMMA_RESPONSE | 0.300 | Idelalisib | — uncovered |
| SPERMATOGENESIS | 0.300 | Inavolisib | — uncovered |
| COAGULATION | 0.280 | Binimetinib | — uncovered |
| INFLAMMATORY_RESPONSE | 0.270 | Idelalisib | — uncovered |
| COMPLEMENT | 0.260 | Inavolisib | — uncovered |
| INTERFERON_ALPHA_RESPONSE | 0.260 | Inavolisib | — uncovered |
| ANDROGEN_RESPONSE | 0.250 | Inavolisib | — uncovered |
| ESTROGEN_RESPONSE_LATE | 0.250 | Idelalisib | — uncovered |
| OXIDATIVE_PHOSPHORYLATION | 0.180 | Remibrutinib | — uncovered |
| TGF_BETA_SIGNALING | 0.180 | Inavolisib | — uncovered |
| APICAL_SURFACE | 0.150 | Temsirolimus | — uncovered |
| MYC_TARGETS_V1 | 0.140 | Inavolisib | — uncovered |
| KRAS_SIGNALING_DN | 0.130 | Remibrutinib | — uncovered |